Coeptis Therapeutics Stock (NASDAQ:COEP)
Previous Close
$14.75
52W Range
$2.31 - $19.19
50D Avg
$14.80
200D Avg
$11.33
Market Cap
$51.44M
Avg Vol (3M)
$48.21K
Beta
-0.50
Div Yield
-
COEP Company Profile
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
COEP Performance
Peer Comparison
| Ticker | Company |
|---|---|
| OSTX | OS Therapies Incorporated |
| CUE | Cue Biopharma, Inc. |
| OTLK | Outlook Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| NRXP | NRx Pharmaceuticals, Inc. |
| MDCX | Medicus Pharma Ltd. Common Stock |
| SNTI | Senti Biosciences, Inc. |
| EQ | Equillium, Inc. |
| TELO | Telomir Pharmaceuticals, Inc. Common Stock |
| KPTI | Karyopharm Therapeutics Inc. |